Search results | hiv

Reports

HIV Partnering

The HIV Partnering provides understanding and access to the HIV partnering deals and agreements entered into by the worlds leading healthcare companies

Age related Macular Degeneration Partnering

Age-related Macular Degeneration Partnering report provides understanding and access to the age-related macular degeneration partnering deals and agreements entered into by the worlds leading healthcare companies.

Glaucoma Partnering

Glaucoma Partnering report provides understanding and access to the glaucoma partnering deals and agreements entered into by the worlds leading healthcare companies.

Wrinkles Partnering

Wrinkles Partnering report provides understanding and access to the wrinkles partnering deals and agreements entered into by the worlds leading healthcare companies.

Wound Healing Partnering

Wound Healing Partnering report provides understanding and access to the wound healing partnering deals and agreements entered into by the worlds leading healthcare companies.

Sun Damage Partnering

Sun Damage Partnering report provides understanding and access to the sun damage partnering deals and agreements entered into by the worlds leading healthcare companies.

Dermatitis Partnering

Dermatitis Partnering report provides understanding and access to the dermatitis partnering deals and agreements entered into by the worlds leading healthcare companies.

Cosmetics Partnering

Cosmetics Partnering report provides understanding and access to the cosmetics partnering deals and agreements entered into by the worlds leading healthcare companies.

Burns Partnering

Burns Partnering report provides understanding and access to the burns partnering deals and agreements entered into by the worlds leading healthcare companies.

Angioedema Partnering

Angioedema Partnering report provides understanding and access to the angioedema partnering deals and agreements entered into by the worlds leading healthcare companies.

Insights

Gilead seeks pharma partners to bolster HIV business

Gilead Sciences is on the lookout for pharma partners for it’s HIV business and has spent $1.2 billion in two years to buy blood cancer drugs.

Aspen Pharmacare – Africa’s biggest generic drugmaker

Aspen Pharmacare specialises in the production of branded and generic pharmaceuticals and is currently the biggest pharmaceutical company in South Africa taking a 15% share of the total market.

M&A rumors for buyout of Achillion Pharmaceuticals by big pharma

UBS analyst Andrew Peters suggested that a recent takeover big in the biotech space of California-based InterMune, Inc.  by Roche was the harbinger of more M&A rumors to come.

Top 15 most partnered therapeutic trends in pharma industry

Current Partnering releases its first update of the article previously published last year on the most partnered therapeutic trends in pharma. The article analyses the most partnered therapeutic targets of 2009-2014 and identifies the areas that have gained in popularity since last year and the new areas that have entered the list

Industry trends in vaccine dealmaking – 2009 to 2014

Industry trends suggest that vaccine research and development is an increasingly active component of healthcare business development. In recent years there has been a significant increase in vaccine partnering and M&A activity.

Asset purchase

An asset purchase is an agreement between a buyer and a seller that finalizes terms…

Industry trends in infectious vaccines dealmaking – 2009 to 2014

Industry trends suggest that infectious vaccines research and development is an increasingly active component of healthcare business development. The last decade has witnessed a significant number of infectious vaccines partnering and M&A activity

Identifying in-licensing opportunities – Sources of partnering opportunities

CP Insight > Insight Toolkit > Finding Partners > Identifying in-licensing opportunities – Sources of partnering opportunities There are numerous sources of information that can be searched in order to compile a long list of potential partnering opportunities – some free of charge and others that require the payment of a subscription (databases) or a one-off fee (research and analyst reports).

Bristol-Myers Squibb

Bristol-Myers Squibb (BMS) is a top pharmaceutical company based in New York, NY, USA.

Novartis

Novartis is a top pharmaceutical company based in Basel, Switzerland

Events

Sorry, your search returned no results.


Deals

ABL and Abbott sign a biotech deal for HIV genotyping analysis

Advanced Biological Laboratories has granted Abbott non-exclusive rights to market ABL’s software suite for HIV genotyping data analysis.

Janssen and ViiV Healthcare announce a HIV pharma deal

Janssen R&D and ViiV Healthcare have announced a pharma deal to combine both its HIV drug  therapies.

Gilead seeks pharma partners to bolster HIV business

Gilead Sciences is on the lookout for pharma partners for it’s HIV business and has spent $1.2 billion in two years to buy blood cancer drugs.

Pharma licensing approval for Gilead Sciences, HIV drug Viread in EU

A pharma licensing authorization was approved for Gilead Sciences, HIV drug, Viread by European Commission

Merck and the ADAP Crisis Task Force announce new agreement to improve access and care for people with HIV

Merck and the ADAP Crisis Task Force (ACTF) announced a number of new initiatives to help struggling state AIDS Drug Assistance Programs (ADAPs) continue to provide access to medicines to people living with HIV. 

Gilead and Boehringer sign license agreement for novel HIV inhibitors

Licensing agreement under which Boehringer Ingelheim has granted Gilead exclusive worldwide rights for the research, development and commercialization of its novel non-catalytic site integrase inhibitors (NCINIs) for HIV. 

BMS, Oncolys ink HIV pact

Bristol-Myers Squibb and Japan’s Oncolys BioPharma have signed a definitive agreement for festinavir, a next-generation, orally available nucleoside reverse transcriptase inhibitor in Phase II development for HIV.

GlaxoSmithKline and Pfizer agreement creates specialist HIV company

The deal will see the drug giants combine their existing HIV product and their pipelines with GSK holding 85% of the company and Pfizer 15%.

Curevac bags $52 million from Bill and Melinda Gates Foundation

The Bill & Melinda Gates Foundation and CureVac announced that the foundation has made a commitment to invest $52 million (€46 million) in CureVac

Gilead and Mylan expand Sovaldi pact

Mylan Laboratories is expanding its hepatitis C licensing agreement with Gilead Sciences to include the non-exclusive rights to manufacture and distribute the investigational NS5A inhibitor GS-5816